Diabetic Retinopathy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Diabetic Retinopathy Market is segmented by Type (Proliferative diabetic retinopathy, Non-proliferative retinopathy), Management Approach and Geography

Diabetic Retinopathy Market Snapshot

Diabetic Retinopathy Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 11.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Certain factors that are driving the market growth include the rising prevalence of diabetes and blindness due to the same, growing geriatric population base, increasing technological advancements in diabetic retinopathy surgical instruments.

Diabetic retinopathy (DR) is a leading cause of vision-loss globally. The most clinically important risk factors for progression to vision loss include the duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. There is an increasing burden of diabetic retinopathy across the globe. As stated by the International Diabetes Federation (IDF), the global prevalence of DR from 2015 to 2019 was around 27%. The lowest prevalence was in Europe at 20.6% and South East Asia at 12.5% and highest in Africa at 33.8%, Middle East and North Africa 33.8%, and the Western Pacific region at 36.2%.

Hence, the rising prevalence of DR, along with the growing awareness and concern over it, are expected to drive the market growth over the forecast period.

Scope of the Report

As per the scope of the report, diabetic retinopathy refers to a diabetes complication that affects eyes, DR results in damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Initially, diabetic retinopathy may cause no symptoms or only mild vision problems. But eventually, it can cause blindness.

By Type
Proliferative Diabetic Retinopathy
Non-proliferative Retinopathy
By Management Approach
Anti-VEGF Drug
Intraocular Steroid Injection
Laser Surgery
Vitrectomy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Proliferative diabetic retinopathy is Expected to Hold Significant Market Share in the Type Segment

Proliferative diabetic retinopathy (PDR): PDR is the most advanced stage of diabetic retinopathy. At this stage, circulation problems deprive the retina of oxygen. As a result, new, fragile blood vessels can begin to grow in the retina and into the vitreous, the gel-like fluid that fills the back of the eye. The new blood vessels may leak blood into the vitreous, clouding vision. 

Symptoms include progressive loss of vision, particularly in those who are not properly followed or treated. The major risk factors for PDR include the duration of diabetes, since 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to a further increase in the prevalence of PDR.

Diabetic Retinopathy Market

North America Dominates the Market and Expected to do Same in the Forecast Period

Over the past decade, the prevalence of diabetes in North America has increased. People with diabetes are at risk for diabetic retinopathy. Diabetic retinopathy is the leading cause of new cases of blindness among adults aged 20 to 74 years in the United States. More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report published by the Centers for Disease Control and Prevention (CDC). Hence with the increasing number of people living with diabetes is expected to contribute to market growth across the entire region.

Diabetic Retinopathy Market

Competitive Landscape

The global Diabetic Retinopathy market is moderately competitive and consists of a few major players. Companies like Alimera Sciences, Allergan plc, BCN Peptides, Genentech, Glycadia Pharmaceuticals, Kowa Group, Novartis AG, Oxurion NV., Regeneron Pharmaceuticals Inc, among others, which hold the substantial market share in the Diabetic Retinopathy market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Diabetes and Blindness Due to The Same

      2. 4.2.2 Growing Geriatric Population Base

      3. 4.2.3 Increasing Technological Advancements in Diabetic Retinopathy Surgical Instruments

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Skilled Ophthalmologists

      2. 4.3.2 Extended Approval Time for Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Proliferative Diabetic Retinopathy

      2. 5.1.2 Non-proliferative Retinopathy

    2. 5.2 By Management Approach

      1. 5.2.1 Anti-VEGF Drug

      2. 5.2.2 Intraocular Steroid Injection

      3. 5.2.3 Laser Surgery

      4. 5.2.4 Vitrectomy

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alimera Sciences

      2. 6.1.2 AbbVie Inc. (Allergan plc)

      3. 6.1.3 BCN Peptides

      4. 6.1.4 Genentech

      5. 6.1.5 Glycadia Pharmaceuticals

      6. 6.1.6 Kowa Group

      7. 6.1.7 Novartis AG

      8. 6.1.8 Regeneron Pharmaceuticals Inc

      9. 6.1.9 Oxurion NV.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Diabetic Retinopathy Market market is studied from 2018 - 2026.

The Diabetic Retinopathy Market is growing at a CAGR of 11.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Genentech, Regeneron Pharmaceuticals, Inc., Abbvie Inc., Alimera Sciences, Oxurion NV. are the major companies operating in Diabetic Retinopathy Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!